Alar Pharmaceuticals (昱展新藥) has made a significant move into the pet health market. On the 30th, the company announced it has filed for a New Animal Drug Application (NADA) with the Animal and Plant Health Inspection Agency (APHIA) of the Ministry of Agriculture for "Bupanlar," a long-acting analgesic for canine osteoarthritis. Approval is expected as early as the second half of 2026.

Clinical and Market Insights:

• Unmet Need: Osteoarthritis affects approximately 20% of dogs over the age of one. Current treatments rely on short-acting NSAIDs, which often carry risks of gastrointestinal, hepatic, and renal side effects with long-term use.
• Product Advantage: Bupanlar is a long-acting opioid-based injectable administered subcutaneously. Its extended-release profile reduces the frequency of dosing and the caregiving burden on pet owners, making it particularly suitable for elderly animals with compromised organ function.
• Market Potential: Global Market Insights estimates the companion animal pain management market will reach US$2 billion in 2025 and grow to US$3.4 billion by 2034 (6.2% CAGR). Alar Pharmaceuticals is currently in talks for international licensing of its ALA-1000 platform for pet chronic pain.

Resource: 昱展新藥送動物新藥查登拚明年H2取證，搶進寵物骨關節炎長效止痛市場